OnKure Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

OnKure Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-86.2%

Buyback Yield

Total Shareholder Yield	-86.2%
Future Dividend Yield	n/a
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Recent dividend and buyback updates

No updates

Recent updates

Analysis Article • Jul 23

Is OnKure Therapeutics (NASDAQ:OKUR) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analysis Article • Mar 29

We're Keeping An Eye On OnKure Therapeutics' (NASDAQ:OKUR) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Seeking Alpha • Oct 24

OnKure: Looking To Alter PI3K Inhibitor Targeting In Breast Cancer And Beyond

Summary Initial OnKure Therapeutics, Inc. data from the phase 1 PIKture-01 study, using OKI-219 for the treatment of patients with PI3Ka-H1047R breast cancer and solid tumors, is expected in Q4 of 2024. OKI-219 has 80X fold improved selectivity PI3K-a targeting versus wild-type PI3K-a, potentially allowing for higher dosing and reducing unwanted off-target effects. The merger with Reneo Pharmaceuticals and $65 million private placement boosts OnKure's cash to $139 million, funding operations into Q4 2026. Significant market opportunity exists with 15% of breast cancer patients expressing the PI3Ka-H1047R mutation, and the company aims to outperform competitors with greater selectivity of OKI-219. Read the full article on Seeking Alpha

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if OKUR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OKUR's dividend payments have been increasing.

Dividend Yield vs Market

OnKure Therapeutics Dividend Yield vs Market

How does OKUR dividend yield compare to the market?
Segment	Dividend Yield
Company (OKUR)	n/a
Market Bottom 25% (US)	1.4%
Market Top 25% (US)	4.2%
Industry Average (Biotechs)	2.4%
Analyst forecast (OKUR) (up to 3 years)	n/a

Notable Dividend: Unable to evaluate OKUR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OKUR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate OKUR's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as OKUR has not reported any payouts.

Discover strong dividend paying companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/01 19:23
End of Day Share Price	2026/06/01 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

OnKure Therapeutics, Inc. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Robert Burns	H.C. Wainwright & Co.
Soumit Roy	JonesTrading Institutional Services, LLC
Andrew Berens	Leerink Partners LLC